PUBLISHER: The Business Research Company | PRODUCT CODE: 1764318
PUBLISHER: The Business Research Company | PRODUCT CODE: 1764318
Fibroblast growth factors (FGFs) are a group of signaling proteins essential for regulating cell growth, tissue repair, and development. They primarily promote fibroblast proliferation and differentiation, playing a key role in processes such as wound healing, embryonic development, angiogenesis, and metabolic regulation.
The major product types of fibroblast growth factors include recombinant fibroblast growth factor, purified fibroblast growth factor, endogenous fibroblast growth factor, and others. Recombinant fibroblast growth factor is synthetically produced through genetic engineering techniques to generate large quantities for therapeutic and research purposes. These are categorized by type into palifermin, erdafitinib, infigratinib, futibatinib, and others. FGFs are used in a wide range of applications, including oncology, hematology, wound healing, dermatology, cardiovascular disease, bone and musculoskeletal disorders, and tissue regeneration. The primary end users include pharmaceutical companies, biotechnology firms, research institutes, and others.
The fibroblast growth factors (FGFs) market research report is one of a series of new reports from The Business Research Company that provides fibroblast growth factors (FGFs) market statistics, including the fibroblast growth factors (FGFs) industry global market size, regional shares, competitors with the fibroblast growth factors (FGFs) market share, detailed fibroblast growth factors (FGFs) market segments, market trends, and opportunities, and any further data you may need to thrive in the fibroblast growth factors (FGFs) industry. This fibroblast growth factors (FGFs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The fibroblast growth factors (FGFs) market size has grown rapidly in recent years. It will grow from $0.86 billion in 2024 to $1.34 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. Growth during the historic period can be attributed to the rising demand for regenerative medicine, increased utilization of FGFs in wound healing applications, growing funding for cancer research, advancements in biopharmaceutical innovation, and heightened awareness of the therapeutic potential of fibroblast growth factors (FGFs).
The fibroblast growth factors (FGFs) market size is expected to see rapid growth in the next few years. It will grow to $1.34 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. Growth in the forecast period is expected to be driven by rising investments in personalized medicine, increased adoption of fibroblast growth factor (FGF)-based therapies, the growing prevalence of chronic diseases, ongoing advancements in biotechnology, and expanding collaborations between pharmaceutical companies and research institutions. Key trends anticipated during this period include progress in targeted drug delivery systems, development of advanced biomaterials for FGF delivery, innovation in gene editing technologies, advancements in sustained-release formulations, and the emergence of novel combination therapies.
The increasing prevalence of chronic diseases is expected to drive the growth of the fibroblast growth factors (FGFs) market in the coming years. Chronic diseases are long-lasting health conditions that develop gradually and often require ongoing medical attention. This rise in chronic illnesses is partly linked to sedentary lifestyles, as reduced physical activity and prolonged sitting heighten the risk of conditions such as heart disease and diabetes. FGFs contribute to managing chronic diseases by facilitating tissue repair and regeneration, making them valuable in the treatment of long-term conditions. They aid healing, slow disease progression, and improve patient outcomes and quality of life. For example, in June 2024, the UK's National Health Service reported that 3,615,330 individuals registered with general practitioners were diagnosed with non-diabetic hyperglycemia (pre-diabetes) in 2023-an 18% increase from 3,065,825 cases in 2022. This surge underscores the growing need for effective therapies like FGFs. Thus, the rising burden of chronic diseases is fueling demand in the FGFs market.
Major companies in the fibroblast growth factors (FGFs) market are prioritizing the development of technologically advanced products, such as engineered FGF variants, to improve therapeutic efficacy, minimize side effects, and support regenerative treatments for chronic and degenerative conditions. Engineered FGF variants are modified forms of fibroblast growth factors designed to enhance stability, target specificity, and potency, thereby optimizing therapeutic outcomes in tissue repair and disease management. For example, in October 2022, Zhittya Genesis Medicine, a US-based biotechnology firm, introduced an innovative FGF-1 therapy aimed at treating Parkinson's disease. This therapy utilizes intranasal delivery to stimulate angiogenesis and neuronal regeneration within the brain. The FGF-1 treatment represents a promising advancement in slowing disease progression and enhancing quality of life for affected individuals.
In January 2022, Thermo Fisher Scientific Inc., a US-based biotechnology company, acquired PeproTech Inc. for approximately $1.85 billion. This acquisition was intended to strengthen Thermo Fisher's capabilities in cell and gene therapy by broadening its portfolio of recombinant proteins, including fibroblast growth factors (FGFs), which are essential components in cell culture media and regenerative medicine applications. PeproTech Inc., also based in the US, is a biotechnology company that specializes in recombinant FGFs for research and regenerative medicine purposes.
Major players in the fibroblast growth factors (fgfs) market are Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Wako Pure Chemical Corporation, Lonza Group AG, Miltenyi Biotec B.V. & Co. KG, GenScript Biotech Corporation, 89bio Inc., R&D Systems Inc., ACROBiosystems Co. Ltd., Elabscience Biotechnology Inc., Cell Signaling Technology Inc., BPS Bioscience Inc., Proteintech Group Inc., Akero Therapeutics Inc., MedChemExpress LLC, Defined Bioscience Inc., Gold Biotechnology Inc. (GoldBio), Nucleus Biologics LLC, ZellBio GmbH, Affinity Biosciences Ltd., GeneCards.
North America was the largest region in the fibroblast growth factors (FGFs) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fibroblast growth factors (FGFs) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the fibroblast growth factors (FGFs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The fibroblast growth factors (FGFs) market consists of sales of fibroblast growth factors (FGFs)-based therapeutic proteins, growth factor supplements for cell culture, and related biologics used in wound healing, tissue regeneration, and cosmetic applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Fibroblast Growth Factors (FGFs) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on fibroblast growth factors (fgfs) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for fibroblast growth factors (fgfs) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fibroblast growth factors (fgfs) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.